Dermatitis Herpetiformis: Pathogenesis & Immunology#
Medical Disclaimer
This content is for informational purposes only. It is not medical advice. Read the full disclaimer.
1. Overview#
Dermatitis herpetiformis (DH) is the cutaneous manifestation of celiac disease (CD), characterized by granular IgA deposits at the dermal-epidermal junction. It is a complex autoimmune disease driven by gluten sensitivity, resulting in an immunological cascade involving IgA autoantibodies, complement activation, neutrophil recruitment, and tissue destruction.
2. The Initiating Event: Gluten and TG2#
The pathogenic cascade begins in the gut:
- Gluten ingestion introduces gliadin peptides into the small intestine
- Tissue transglutaminase (TG2) deamidates specific glutamine residues in gliadin, converting them to glutamic acid
- Deamidated gliadin peptides bind with high affinity to HLA-DQ2 (DQ2.5: DQA105:01/DQB102:01) or HLA-DQ8 molecules on antigen-presenting cells
- The Lys-beta71 hydrogen bonding network in HLA-DQ2 creates a preferential binding pocket for negatively charged (deamidated) peptides
- CD4+ gliadin-specific T cells are activated, driving the adaptive immune response
Key molecular detail: TG2 also forms covalent complexes with gliadin (TG2-gliadin complexes), which are critical for B-cell activation via the hapten-carrier model.
Sources: StatPearls - DH, Medscape - DH Pathophysiology
3. B-Cell Activation and Antibody Production#
B-cell activation follows the hapten-carrier model:
- B cells with surface receptors for TG2 (or TG3) internalize TG-gliadin complexes
- These B cells process and present gliadin peptides to gliadin-specific CD4+ T cells
- T-cell help drives B-cell differentiation into plasma cells
- Plasma cells produce IgA antibodies against TG2, TG3, and deamidated gliadin
2025 finding (Nature Communications): Stereotypic B-cell receptors using IGHV2-5/IGKV4-1 gene segments have been identified in DH patients. These BCRs enhance TG3 catalytic activity, potentially amplifying the autoimmune response.
Antibody classes produced: - Anti-TG2 IgA (gut-predominant) - Anti-TG3 IgA (skin-predominant, the DH-specific autoantibody) - Anti-deamidated gliadin peptide (DGP) IgA and IgG - Anti-endomysial antibodies (EMA)
Sources: PMC - Antibody Responses to TG3 in DH, J Exp Med - TG3 as Autoantigen
4. TG2 vs TG3: The Critical Distinction#
| Feature | TG2 (Tissue Transglutaminase) | TG3 (Epidermal Transglutaminase) |
|---|---|---|
| Location | Ubiquitous; concentrated in gut | Epidermis, hair follicles |
| Size | 78 kDa | 77 kDa (692 amino acids) |
| Function | Deamidation of gliadin, cross-linking ECM proteins | Cross-links involucrin, loricrin, filaggrin (cornified envelope formation) |
| Role in disease | Primary autoantigen in celiac disease | Primary autoantigen in DH skin |
| Antibodies | Present in both CD and DH | DH-specific; absent in CD-only patients |
| Deposits | Gut mucosa | Papillary dermis |
TG3 as the DH autoantigen: Identified by Sárdy et al. (2002) in the Journal of Experimental Medicine. TG3 is a zymogen that requires proteolytic activation. In the skin, TG3 is released from keratinocytes and deposited in the papillary dermis, where it binds circulating IgA anti-TG3 antibodies.
Sources: J Exp Med - Epidermal TG as Autoantigen, PubMed - Elevation of IgA anti-eTG
5. Epitope Spreading: From TG2 to TG3#
The development of DH in patients with celiac disease is explained by epitope spreading:
- Initial immune response targets TG2 in the gut (celiac disease)
- Progressive expansion of the antibody repertoire over time
- Cross-reactivity develops between TG2 and TG3 (77% sequence homology)
- B cells autoreactive to TG3 evade tolerance mechanisms
- These B cells localize to the intestine, internalize TG3-gliadin complexes, and present gliadin peptides to T cells
- Anti-TG3 IgA production begins → DH develops
Clinical implication: This explains why DH typically develops years to decades after the onset of (often undiagnosed) celiac disease. The progressive expansion of the epitope-binding profile during adult life accounts for the typical age of DH onset (30s-40s).
Sources: PMC - Antibody Responses to TG3, Acta Derm Venereol - Pathognomonic TG IgA
6. The Gut-Skin Axis#
The connection between intestinal and cutaneous disease is the central mystery of DH:
How intestinal damage leads to skin lesions:#
Hypothesis 1: Circulating immune complexes - IgA-TG3 complexes form in the circulation - These complexes deposit in the papillary dermis due to local factors (mechanical stress, vascular anatomy)
Hypothesis 2: Local assembly - TG3 is released from damaged keratinocytes into the papillary dermis - Circulating IgA anti-TG3 antibodies bind locally deposited TG3 - Complexes assemble in situ
Key evidence: - Virtually all DH patients have enteropathy (though often subclinical) - Clinically silent but immunologically active celiac disease drives IgA-TG3 production - Intestinal plasma cells produce the anti-TG3 IgA that deposits in skin - GFD resolves both gut and skin disease (though skin clears much more slowly)
Sources: Acta Derm Venereol - DH Review, Frontiers - DH Novel Perspectives
7. IgA Subclasses in DH#
- Skin deposits: 100% IgA1 (not IgA2)
- Circulation: Mixed IgA1 and IgA2
- IgA1 predominance in skin may reflect the mucosal origin of the antibodies (intestinal plasma cells produce predominantly IgA1)
- The granular pattern of IgA deposits at the dermal papillae tips is pathognomonic for DH
Sources: StatPearls - DH
8. IgA-TG3 Complex Deposition in Skin#
- Complexes deposit in the papillary dermis, specifically at the tips of dermal papillae
- Deposition pattern is granular (distinguishing DH from linear IgA bullous dermatosis)
- Some patients show a fibrillar pattern (1.2-56% depending on ethnicity) associated with dermal microfibrils
- Deposits can persist for up to 10 years on a strict gluten-free diet
- 24% of patients on strict GFD lost skin IgA deposits in 3-16 months
- Deposits return rapidly upon reintroduction of gluten
Mechanical factors: Stretching/pressure may activate deposited TG3 enzyme, which then binds fibrinogen, initiating the inflammatory cascade. This may explain the predilection for extensor surfaces.
Sources: PubMed - 25 years GFD experience, PMC - Persistent Skin Symptoms
9. Complement Activation#
DH involves activation of the alternative complement pathway:
- C3 deposits found at the dermal-epidermal junction in a pattern similar to IgA
- Factor B and properdin detected (markers of alternative pathway)
- Formation of C5b-9 membrane attack complex (MAC)
- C5a generated as a potent neutrophil chemoattractant
- Complement activation amplifies the inflammatory response and contributes to tissue damage
Note: Classical pathway activation is NOT the primary mechanism (consistent with IgA involvement, as IgA does not efficiently activate the classical pathway).
Sources: PMC - Etiopathogenesis of DH, PMC - DH Genetics to Skin Lesions
10. Endothelial Activation#
A striking feature of DH pathogenesis:
- E-selectin mRNA expression: 1,271x normal in lesional skin
- ICAM-1 upregulated on endothelial cells
- Indicates a systemic pro-inflammatory state affecting dermal vasculature
- Facilitates neutrophil rolling, adhesion, and transmigration
- Immunoglobulin and complement deposits found in cutaneous vessels
Sources: PubMed - Immunoglobulin and Complement in Cutaneous Vessels
11. Neutrophil Recruitment and Activation#
Neutrophils are the primary effector cells in DH skin lesions:
Recruitment cascade:#
- IgA binds FcαRI (CD89) on neutrophils
- CD11b is upregulated on circulating neutrophils (even in uninvolved skin areas)
- L-selectin shedding occurs, facilitating tissue migration
- Chemotactic signals: IL-8, C5a, GM-CSF, LTB4
- Neutrophils migrate to the papillary dermis
Neutrophil activation in tissue:#
- Respiratory burst via NOX2/MPO (NADPH oxidase / myeloperoxidase system)
- Release of reactive oxygen species (ROS)
- Degranulation releases proteases
Sources: PMC - Etiopathogenesis of DH, Medscape - DH Pathophysiology
12. Cytokine Network#
| Cytokine | Role in DH | Source |
|---|---|---|
| IL-8 | Primary neutrophil chemoattractant; elevated in serum and basal epidermis; production provoked by gluten in intestine | Keratinocytes, macrophages |
| TNF-α | Pro-inflammatory; amplifies endothelial activation | Macrophages, T cells |
| IL-4 | Th2 cytokine; elevated in DH skin (contrasting Th1 gut response) | T cells |
| IL-5 | Eosinophil recruitment and activation | T cells |
| IL-6 | Pro-inflammatory; acute phase response | Multiple cell types |
| IL-13 | Th2 cytokine; tissue remodeling | T cells |
| IL-17 | Th17 response; neutrophil recruitment amplification | Th17 cells |
| IFN-γ | Th1 cytokine; predominates in gut, less in skin | T cells |
| GM-CSF | Neutrophil survival and activation | T cells, keratinocytes |
| Eotaxin | Eosinophil chemotaxis; concentrated at papillae tips | Keratinocytes, fibroblasts |
Important distinction: DH skin shows a Th2/Th17-predominant cytokine profile, while celiac gut shows a Th1-predominant profile. This divergence may explain why the same disease manifests differently in two tissues.
Sources: PubMed - Th2-like Cytokine Activity in DH, Wiley - Gene Expression Profiling in DH
13. Eosinophil Involvement#
Often overlooked, eosinophils play a significant role:
- Eosinophil cationic protein (ECP) elevated in DH
- Eosinophil extracellular DNA traps detected in lesional skin
- Eotaxin concentrated at dermal papillae tips (matching lesion distribution)
- IL-5 from Th2 cells drives eosinophil recruitment
- Eosinophils contribute to tissue damage through degranulation and trap formation
Sources: PMC - DH Genetics to Skin Lesions
14. Blister Formation: The Destructive Cascade#
The subepidermal blisters in DH result from proteolytic destruction of the basement membrane zone:
Proteases involved:#
- Neutrophil elastase → cleaves collagen VII (anchoring fibrils)
- MMP-1 (collagenase-1) → degrades interstitial collagen
- MMP-3 (stromelysin-1) → broad-spectrum ECM degradation
- ADAM 8, 10, 15, 17 → metalloproteinases contributing to tissue destruction
Additional damage:#
- Reactive oxygen species via NOX2/MPO system
- Destruction of laminin and type IV collagen (basement membrane components)
- Damage to anchoring fibrils (collagen VII)
- Result: separation at the dermal-epidermal junction → subepidermal vesicle
Sources: PMC - Etiopathogenesis of DH, Medscape - DH
15. Histopathology#
H&E findings:#
- Neutrophilic microabscesses (Pierard microabscesses) at the tips of dermal papillae
- Subepidermal vesicle/blister formation
- Fibrin deposition in papillary dermis
- Nuclear dust (leukocytoclasis) from degranulated neutrophils
- Mixed inflammatory infiltrate (neutrophils predominant, with eosinophils and lymphocytes)
- Perivascular lymphocytic infiltrate in upper dermis
Direct Immunofluorescence (DIF) - Gold Standard:#
- Granular IgA deposits at the tips of dermal papillae (pathognomonic)
- Fibrillar IgA pattern in a subset (1.2-56% depending on ethnicity), associated with dermal microfibrils
- C3 co-deposits common
- Biopsy must be taken from perilesional uninvolved skin (not lesional skin, where inflammation destroys the diagnostic pattern)
Sources: Pathology Outlines - DH, StatPearls - DH
16. DH vs Celiac Disease: Immune Response Comparison#
| Feature | Celiac Disease (Gut) | DH (Skin) |
|---|---|---|
| Primary autoantigen | TG2 | TG3 |
| Ig deposits | IgA anti-TG2 in gut mucosa | IgA anti-TG3 in papillary dermis |
| T-cell response | Th1-predominant (IFN-γ) | Th2/Th17-predominant (IL-4, IL-5, IL-17) |
| Effector cells | CD8+ intraepithelial lymphocytes | Neutrophils (primary), eosinophils |
| Tissue damage | Villous atrophy, crypt hyperplasia | Subepidermal vesicles, papillary microabscesses |
| Inflammatory pattern | Lymphocytic | Neutrophilic/granulocytic |
| Clinical onset | Often childhood/young adult | Typically 30s-40s (after years of CD) |
Sources: Frontiers - DH Novel Perspectives
17. Timeline: From Gluten Exposure to Skin Eruption#
- Hours to days: Gluten exposure → intestinal immune activation
- Days to weeks: Acute flare of existing skin lesions after gluten challenge
- Months to years: Development of DH in a patient with existing (often undiagnosed) CD
- 6 months to 2+ years: Time for GFD to control skin disease without dapsone
- Up to 10 years: Complete clearance of IgA deposits from skin on strict GFD
- >1/3 of patients still have skin symptoms 2 years after diagnosis on GFD
- 14% have ongoing symptoms after long-term dietary treatment
Sources: PubMed - 25 Years GFD Experience, PMC - Persistent Skin Symptoms
18. Dapsone: Mechanism of Action in DH#
Dapsone provides rapid symptomatic relief (1-3 days) through multiple anti-inflammatory mechanisms:
- MPO inhibition: Blocks the myeloperoxidase-peroxide-halide cytotoxic system, reducing neutrophil-mediated oxidative damage
- CD11b/CD18 interference: Suppresses integrin-mediated neutrophil adherence and transmigration
- Signal transduction inhibition: Interferes with G-protein (Gi type) activation, suppressing second messenger generation essential to neutrophil activation
- Leukotriene inhibition: Blocks LTB4-mediated chemotaxis
- IgA adhesion reduction: Decreases neutrophil binding to IgA
- IL-8 pathway modulation: Indirect reduction in neutrophil chemotaxis
Important: Dapsone treats symptoms but does NOT address the underlying autoimmune process. It does not clear IgA deposits or reverse intestinal damage.
Sources: PubMed - Dapsone Modes of Action, PubMed - Dapsone Suppresses Integrin-Mediated Adherence
19. Animal Models#
- SCID mouse/human skin graft model: Passive transfer of TG3 antibodies into mice bearing human skin grafts demonstrates that anti-TG3 IgA is sufficient to reproduce DH-like deposits, proving the pathogenic role of TG3 autoantibodies
- No spontaneous animal model of DH exists (the disease appears uniquely human)
- This limits preclinical testing of new therapies
Sources: PMC - DH Genetics to Skin Lesions
20. Alcohol as a Disease Amplifier#
Alcohol interacts with the DH pathogenic cascade through at least three mechanisms:
20.1 Alcohol Induces Gluten Sensitization#
A case-control study of 904 patients found that 44% of heavy alcohol users developed antigliadin antibodies (vs 12% of healthy controls), and 61% carried HLA-DQ2/DQ8 (vs 30% of controls). The proposed mechanism: alcohol damages the intestinal mucosa → increased gut permeability → gliadin peptides cross the barrier → immune sensitization occurs in genetically susceptible individuals. Notably, none of these patients had celiac disease, suggesting alcohol alone can initiate gluten immune reactivity.
Source: PMC - Alcohol Induces Sensitization to Gluten
20.2 Alcohol Triggers Anti-TG2 IgA Responses#
Excessive alcohol consumption mediates an IgA immune response directed against tissue transglutaminase (TG2) — the same autoantigen that initiates the celiac/DH cascade. This means alcohol doesn't just allow gluten through the gut barrier; it may independently activate the same autoimmune pathway that drives IgA production and, via epitope spreading, anti-TG3 IgA deposition in skin.
20.3 Alcohol Increases Gut Permeability#
Even moderate alcohol consumption (1-2 standard drinks/day) worsens intestinal permeability via the zonulin pathway. In celiac patients whose gut barrier is already compromised, this effect amplifies gluten peptide translocation, increasing immune activation and antibody production.
Practical Implications for DH Patients#
| Beverage | Risk Level | Reason |
|---|---|---|
| Beer (standard) | High | Contains barley-derived gluten + alcohol permeability effect |
| "Gluten-reduced" beer | Uncertain/risky | Enzymatic treatment may leave immunotoxic polypeptides |
| Wine | Low (gluten) | No gluten source; alcohol permeability effect still applies |
| Distilled spirits | Low (gluten) | Distillation removes proteins; alcohol permeability effect still applies |
Key insight: Beer represents a double hit — gluten exposure combined with alcohol-mediated barrier disruption. Even "gluten-free" alcoholic beverages still compromise gut permeability, potentially amplifying the immune response to any incidental gluten exposure.
Source: PMC - Barley-Based Gluten Free Beer Risks
21. Key Unresolved Questions#
- Why do only ~15-25% of celiac patients develop DH?
- What determines the specific sites of IgA-TG3 deposition in skin?
- Why does mechanical stress/pressure correlate with lesion distribution?
- What triggers the switch from TG2-only to TG2+TG3 autoimmunity?
- Why does the skin show Th2/Th17 while the gut shows Th1?
- Can IgA deposits be actively cleared rather than waiting years for passive resolution?
- What role does the skin microbiome play in lesion localization?
Document compiled from PubMed, PMC, Medscape, Frontiers in Immunology, Acta Dermato-Venereologica, Journal of Experimental Medicine, and other peer-reviewed sources. February 2026.